What a 21% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
The archive
Page 148 of 170 of this archive, newest first.
What the new Saudi Arabia guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Inspectors cite the online reseller trading as Adamant Research Supply over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the trials counted as intolerance
We set out the questions that distinguish a symptom to manage from a dose to change.
The intramuscular injection nobody intended
A 4 mm needle at ninety degrees without a skin pinch is adequate for essentially all adults. The persistence of 12.7 mm needles in this market is habit, not reasoning.
A tested vial is evidence about a vial
A result on one vial generalises to a batch only if the vial was drawn in a way that makes it representative — and nobody records how it was drawn.
Japan health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
STEP 3 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Turkey pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
The quiet end of the online reseller trading as Adamant Research Supply
A proper account of an operation that existed, and of what closing it cost.
Forty-four per cent: reading the nausea figure properly
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
STEP 4 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why summer is a documented quality problem in this trade
The route did not close because of a rule about peptides.
From the floor in Zhuhai: 8 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why the customs shed is the least documented step in this trade
Degradation rates rise exponentially with temperature while an arithmetic mean adds linearly. Mean kinetic temperature is the weighting that reconciles the two, and it is…
The isotope pattern tells you the charge, and the charge tells you the mass
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
What a 39% rise in coupling-reagent prices does to a 2 mg vial
Follow the resin, not the catalogue.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Independent analysis puts a QST survodutide lot at 96.3%, against 95.4% on the certificate
A reminder that a purity figure is the output of a method, and that methods differ.
What the placebo arms of the withdrawal trials actually tell us
The evidence on stopping is better than the evidence on almost anything else in this field, because somebody deliberately randomised it.
We split six vials four ways and posted them
Duplicate submissions under different names test within-laboratory repeatability, which is a different quantity from between-laboratory reproducibility.
What changed at WWB in April, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
The 15-day notice: how a compounding wind-down works in Portugal
The document is four pages. Three of them are about dates.
The online reseller trading as Adamant Research Supply closes after 13 years
A proper account of an operation that existed, and of what closing it cost.
Germany caps dulaglutide prescribing to 24 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
Manual reintegration is legitimate, and it should be declared
We work through a single chromatogram twice, under two integration conventions, and show where the difference comes from.
Why people actually stop, in the order they actually stop
Cost is the modal reason for discontinuation in every dataset we have seen, and it is absent from the clinical literature.
SURMOUNT-2 misses on a secondary endpoint the coverage has not mentioned
A design note rather than a result: what the comparator was, and what that permits you to conclude.
A shortage listing ends. 19 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.